Study Summary
This is a single center,randomized ,two-cohorts, open-label ,phase 1/2 study to evaluate the efficacy and safety of T cells expressing CD19 chimeric antigen receptors treatment for relapsed/refractory CD19+ acute lymphoblastic leukemia patients.
Want to learn more about this trial?
Request More InfoInterventions
CD19 CAR-T cellsBIOLOGICAL
Express a Second Generation 4-1BB: CD19 CAR-T cells
CD19 CAR-T cells with CRS suppression technologyBIOLOGICAL
Express a Second Generation 4-1BB:CD19 CAR-T cells with CRS suppression technology
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| The first affiliated hospital of soochow university | Suzhou | Jiangsu | China |